At 12 months, however, a statistically significantly higher complete response rate was reported in the benralizumab arm vs the mepolizumab arm (48.1% vs 32.4%, respectively; P =.005).

The upcoming release of Phase III Fasenra (benralizumab) data in COPD, anticipated in 2025, is expected to solidify AstraZeneca’s position in the market and accelerate the adoption of biologics for ...

TUESDAY, Dec. 10, 2024 (HealthDay News) -- Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD), according to a ...

Benralizumab, a monoclonal antibody, is already used for the long-term management of eosinophilic asthma, with studies still evaluating the effect for long-term management in eosinophilic COPD ...

A new way of treating serious asthma and chronic obstructive pulmonary disease (COPD) attacks could be a “game-changer” and is the first leap in treatment for 50 years, researchers say.

Benralizumab is the first treatment for asthma attacks and chronic obstructive pulmonary disease (COPD) in 50 years. The drug, which is delivered by an injection, helps to treat flare-ups of the ...

Benralizumab is the first treatment for asthma attacks and chronic obstructive pulmonary disease (COPD) in 50 years. The drug, which is delivered by an injection, helps to treat flare-ups of the ...

The drug, which is called benralizumab, is the first new treatment for asthma attacks and chronic obstructive pulmonary disease (COPD) in 50 years. A trial has shown that using the drug can cut ...

The adjusted percentage of patients with remission at weeks 36 and 48 was 59% in the benralizumab group and 56% in the mepolizumab group (difference, 3 percentage points; 95% CI, –13 to 18; P ...

Benralizumab, an anti–interleukin-5 receptor alpha monoclonal antibody, was significantly better than placebo at producing a histologic response of up to six eosinophils per high-power field ...